Nothing Special   »   [go: up one dir, main page]

Steinberg, 2016 - Google Patents

Overview of sickle cell anemia pathophysiology

Steinberg, 2016

Document ID
12761866715531747500
Author
Steinberg M
Publication year
Publication venue
Sickle cell anemia: from basic science to clinical practice

External Links

Snippet

Sickle cell disease, caused by a mutation in the β-hemoglobin gene, is a Mendelian disorder with a very diverse phenotype. The primary cause of disease pathophysiology is the deoxygenation-induced polymerization of the mutant sickle hemoglobin. This ultimately …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Steinberg Overview of sickle cell anemia pathophysiology
Alaarg et al. Red blood cell vesiculation in hereditary hemolytic anemia
Flores et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis
Westerman et al. Red blood cell-derived microparticles: An overview
Potoka et al. Vasculopathy and pulmonary hypertension in sickle cell disease
Steinberg Pathophysiologically based drug treatment of sickle cell disease
Belcher et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
Hayes et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration
Steinberg Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches
Kaul et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice
Gauvin et al. Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients
Madigan et al. Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease
De Franceschi et al. Oxidative Stress and β‐Thalassemic Erythroid Cells behind the Molecular Defect
Kato et al. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine and new research directions
Silliman et al. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury
Rogers et al. Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity
Rogers et al. Hypoxia limits antioxidant capacity in red blood cells by altering glycolytic pathway dominance
Cabrales et al. Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide
Momi et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
McArthur et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease
Morabito et al. H2O2-induced oxidative stress affects SO4= transport in human erythrocytes
Hänggi et al. Red blood cells of sickle cell disease patients exhibit abnormally high abundance of N‐methyl D‐aspartate receptors mediating excessive calcium uptake
Wajih et al. Potential therapeutic action of nitrite in sickle cell disease
Patel et al. The effect of hydroxyurea on compound heterozygotes for sickle cell‐hemoglobin D‐Punjab—a single centre experience in eastern India
Kaddam et al. Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study